Drugs / BMS-986528
last change 18 days ago re-read 3 minutes ago

BMS-986528

Developed for
rheumatoid arthritis
Investigated by
Bristol-Myers Squibb

Trials 1

202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07412704 Sep 2026 → Oct 2029 expected rheumatoid arthritis Bristol-Myers Squibb Not yet recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BMS-986528 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07412704 ↗